1. Home
  2. AYTU vs AWH Comparison

AYTU vs AWH Comparison

Compare AYTU & AWH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • AWH
  • Stock Information
  • Founded
  • AYTU N/A
  • AWH 1993
  • Country
  • AYTU United States
  • AWH United States
  • Employees
  • AYTU N/A
  • AWH N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • AWH Medical/Dental Instruments
  • Sector
  • AYTU Health Care
  • AWH Health Care
  • Exchange
  • AYTU Nasdaq
  • AWH Nasdaq
  • Market Cap
  • AYTU 15.0M
  • AWH 13.5M
  • IPO Year
  • AYTU N/A
  • AWH N/A
  • Fundamental
  • Price
  • AYTU $2.36
  • AWH $0.82
  • Analyst Decision
  • AYTU
  • AWH Buy
  • Analyst Count
  • AYTU 0
  • AWH 2
  • Target Price
  • AYTU N/A
  • AWH $4.40
  • AVG Volume (30 Days)
  • AYTU 29.8K
  • AWH 68.9K
  • Earning Date
  • AYTU 11-12-2024
  • AWH 11-11-2024
  • Dividend Yield
  • AYTU N/A
  • AWH N/A
  • EPS Growth
  • AYTU N/A
  • AWH N/A
  • EPS
  • AYTU N/A
  • AWH N/A
  • Revenue
  • AYTU $81,002,000.00
  • AWH $8,923,000.00
  • Revenue This Year
  • AYTU N/A
  • AWH $15.59
  • Revenue Next Year
  • AYTU N/A
  • AWH $108.47
  • P/E Ratio
  • AYTU N/A
  • AWH N/A
  • Revenue Growth
  • AYTU N/A
  • AWH N/A
  • 52 Week Low
  • AYTU $2.20
  • AWH $0.74
  • 52 Week High
  • AYTU $3.50
  • AWH $6.01
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 44.84
  • AWH 39.72
  • Support Level
  • AYTU $2.26
  • AWH $0.74
  • Resistance Level
  • AYTU $2.47
  • AWH $0.87
  • Average True Range (ATR)
  • AYTU 0.15
  • AWH 0.06
  • MACD
  • AYTU -0.01
  • AWH 0.02
  • Stochastic Oscillator
  • AYTU 16.10
  • AWH 48.24

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.

About AWH Aspira Women's Health Inc.

Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.

Share on Social Networks: